Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: US Public Confidence In COVID-19 Vaccines Declines

Plus: Canada Signs Deals With Sanofi/GSK And Moderna

Executive Summary

Confidence in the vaccine has slipped in the US, regardless of political affiliation.

You may also be interested in...



Coronavirus Update: Trump Tests Positive, US Pause Remains On AstraZeneca Vaccine

Meanwhile, seven former US FDA commissioners issue joint plea for trust in the scientific integrity of the agency.

Trust Us: Is Pharma’s COVID-19 Vaccine Pledge Convincing?

Missteps on convalescent plasma and the revoked authorization of hydroxychloroquine – paired with US president Trump’s cheerleading for the rapid approval of a COVID-19 vaccine – has eroded public trust in the US FDA. Can a safety and efficacy pledge from vaccine developers tamp down public skepticism?

AstraZeneca CEO: 2020 Approval For COVID Vaccine Still Possible

While AZ awaits an independent review, its CEO maintains the vaccine could soon be back on track for a late 2020/early 2021 approval.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel